We discover, develop and deliver neurological therapies for patients with unmet medical needs.
Équilibre Biopharmaceuticals Corp. was established as an innovative biopharmaceutical company focused on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications.
Our approach is to leverage our biopharmaceutical industry expertise to further expand our portfolio of product opportunities. Our business strategy is designed to be flexible and nimble, which allows us to develop a broad array of new therapies with clinical and commercial potential.
We’re driven by our passion to help patients. In pursuit of the betterment of patients, we encourage and promote collaboration and teamwork among our employees and those of our partners to potentially accelerate drug developments and foster best practices.
"My founding vision for Équilibre Biopharmaceuticals is to develop new generations of medicines that will meaningfully improve the lives of patients by addressing drug resistance or limited efficacy of current therapies, while also reducing side effects and improving the quality of life for patients living with neurodegenerative diseases. We are focused on developing novel therapeutic agents for the most difficult-to-treat conditions, specifically targeting indications for which conventional therapies have failed. We have created a pipeline of differentiated and novel investigational therapeutic candidates that target some of the most critical pathways for patients with neurodegenerative diseases. We have demonstrated, in preclinical studies, the potential of those candidates to significantly improve outcomes over current standards of care and are excited to be able to one day offer these options to patients." Samuel D. Waksal, Chairman and Chief Executive Officer
Our goal is to be at the forefront of prolific scientific research and development with multiple programs in preclinical and clinical development. Our clinical pipeline includes treatments in several therapeutic areas, including: epilepsy patients who suffer from focal seizure disorders, seizure disorders associated with traumatic brain injury, spasticity associated with spinal chord injury, and Development and Epileptic Encephalopahy, including Lennox-Gastaut syndrome, Dravet syndrome and CDKL5 deficiency disorder.
What’s in a
Our name is derived from the French phrase “tenir en équilibre,” which means to be balanced.
To help patients achieve stability, we are devoted to discovering and developing medicines that restore the consistency of the biological systems optimal for survival.